multicent evalu efficaci toler safeti new first-lin antihypertens drug isradipin latin-american popul isradipin new antihypertens dihydropyridin calcium antagonist efficaci toler safeti ambulatori patient mild-to-moder hypertens design present studi two-week wash-out period confirm diseas week activ treatment mg isradipin patient antihypertens drug diuret beta-block dose isradipin unchang studi mean decreas mm Hg systol blood pressur sbp mm Hg diastol blood pressur dbp heart rate unchang differ beats/min mean bodi weight studi patient isradipin side effect present treatment period clinic laboratori paramet electrocardiograph interv unchang conclus result isradipin novel drug effect treatment mild hypertens group patient 